Anti-IL13 antibodies and uses thereof

Patent metadata

Field	Value
Publication number	US-9605065-B2
Application number	US-201313971394-A
Country	US
Kind code	B2
Filing date	Aug 20, 2013
Priority date	Dec 23, 2003
Publication date	Mar 28, 2017
Grant date	Mar 28, 2017

Abstract

The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.

First claim

The invention claimed is:

1. A method for treating atopic dermatitis in a patient, comprising administering to a patient in need thereof an effective amount of a monoclonal anti-interleukin-13 (“IL-13”) antibody that specifically binds human IL-13, wherein the anti-IL-13 antibody comprises a heavy chain variable region and a light chain variable region comprising the complementarity determining regions of an antibody produced by the hybridoma designated with American Type Culture Collection (“ATCC”) accession number PTA-5657.

2. A method for treating atopic dermatitis in a patient, comprising administering to a patient in need thereof an effective amount of a monoclonal anti-IL-13 antibody that specifically binds human IL-13, wherein the anti-IL-13 antibody comprises a heavy chain variable region comprising complementarity determining regions CDRH1, CDRH2 and CDRH3 having the amino acid sequences of SEQ ID NO: 117, SEQ ID NO: 123, and SEQ ID NO: 135, respectively; and wherein the anti-IL-13 antibody comprises a light chain variable region comprising complementarity determining regions CDRL1, CDRL2 and CDRL3 having the amino acid sequences of SEQ ID NO: 99, SEQ ID NO: 104, and SEQ ID NO: 115, respectively.

3. The method of claim 1 , wherein the heavy chain variable region comprises complementarity determining regions CDRH1, CDRH2 and CDRH3 having the amino acid sequences of SEQ ID NO: 117, SEQ ID NO: 123, and SEQ ID NO: 135, respectively.

4. The method of claim 1 , wherein the light chain variable region comprises complementarity determining regions CDRL1, CDRL2 and CDRL3 having the amino acid sequences of SEQ ID NO: 99, SEQ ID NO: 104, and SEQ ID NO: 115, respectively.

5. The method of claim 1 , wherein the anti-IL-13 antibody further comprises human framework regions.

6. The method of claim 2 , wherein the anti-IL-13 antibody comprises the amino acid sequence of SEQ ID NO: 142, and the amino acid sequence of SEQ ID NO: 143.

7. The method of claim 2 , wherein the anti-IL-13 antibody is an IgG antibody.

8. The method of claim 2 , wherein the anti-IL-13 antibody is an IgG1, an IgG2, an IgG3 or an IgG4 antibody.

9. The method of claim 1 , wherein the anti-IL-13 antibody is humanized.

10. The method of claim 2 , wherein the anti-IL-13 antibody is humanized.

11. The method of claim 1 , wherein the anti-IL-13 antibody is a monovalent antibody, a multispecific antibody, a chimeric antibody, a single chain antibody, a Fab fragment, or a F(ab′) fragment.

12. The method of claim 2 , wherein the anti-IL-13 antibody is a monovalent antibody, a multispecific antibody, a chimeric antibody, a single chain antibody, a Fab fragment, or a F(ab′) fragment.

13. The method of claim 1 , wherein the anti-IL-13 antibody is a bispecific antibody.

14. The method of claim 2 , wherein the anti-IL-13 antibody is a bispecific antibody.

15. The method of claim 6 , wherein the anti-IL-13 antibody is a bispecific antibody.

16. The method of claim 10 , wherein the anti-IL-13 antibody is a bispecific antibody.

17. The method of claim 1 , wherein the anti-IL-13 antibody is conjugated to a molecule.

18. The method of claim 2 , wherein the anti-IL-13 antibody is conjugated to a molecule.

19. The method of claim 6 , wherein the effective amount is between 0.1 mg/kg and 20 mg/kg.

20. A method for treating atopic dermatitis in a patient, comprising administering to a patient in need thereof an effective amount of a monoclonal anti-IL-13 antibody that specifically binds human IL-13, wherein the anti-IL-13 antibody comprises a heavy chain variable region comprising complementarity determining regions CDRH1, CDRH2 and CDRH3 and a light chain variable region comprising complementarity determining regions CDRL1, CDRL2 and CDRL3, wherein:
a. CDRH1 has the amino acid sequence of SEQ ID NO: 117, 118, 119, 120, 121 or 122;
b. CDRH2 has the amino acid sequence of SEQ ID NO: 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133 or 134;
c. CDRH3 has the amino acid sequence of SEQ ID NO: 135, 136, 137, 138, 139, 140 or 141;
d. CDRL1 has the amino acid sequence of SEQ ID NO: 99, 100, 101, 102, or 103;
e. CDRL2 has the amino acid sequence of SEQ ID NO: 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, or 114; and
f. CDRL3 has the amino acid sequence of SEQ ID NO: 115 or 116.

21. A method for treating atopic dermatitis in a patient, comprising administering to a patient in need thereof an effective amount of a monoclonal anti-IL-13 antibody that specifically binds human IL-13, wherein the anti-IL-13 antibody binds to the same epitope of human IL-13 as an antibody produced by the hybridoma designated with ATCC accession number PTA-5657.

22. The method of claim 21 , wherein said antibody competitively inhibits binding of an antibody produced by the hybridoma designated with ATCC accession number PTA-5657 to human IL-13 by at least 50%.

23. The method of claim 21 , wherein said antibody competitively inhibits binding of an antibody produced by the hybridoma designated with ATCC accession number PTA-5657 to human IL-13 by at least 60%.

24. The method of claim 21 , wherein said antibody competitively inhibits binding of an antibody produced by the hybridoma designated with ATCC accession number PTA-5657 to human IL-13 by at least 70%.

Assignees

• Genentech Inc

Inventors

• Fung Sek Chung
• Moyle Matthew
• Lu Mason
• Yan Changning
• Singh Sanjaya
• Huang Dan

Classifications

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/04

  specific for metastasis · CPC title

• A61P31/12

  Antivirals · CPC title